Rowan E. Chapman net worth and biography

Rowan Chapman Biography and Net Worth

Director of Natera
Rowan Chapman has served as a member of our board of directors since August 2019. Dr. Chapman is a founder, investor, and active independent board member. She most recently held senior roles as Head of Johnson & Johnson Innovation, Western North America, Australia and New Zealand, and as Head of Precision Diagnostics at GE Healthcare Life Sciences, Managing Director of New Business Creation, and Head of Healthcare Investing at GE Ventures. Prior to that, she held operational roles in early and growth-stage startups and was a partner at Mohr Davidow Ventures for over 11 years, gaining extensive experience as a board member and board advisor for a wide variety of tech and data-enabled companies. Dr. Chapman holds a Bachelor of Arts degree in Biochemistry and a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Cambridge, United Kingdom.

What is Rowan E. Chapman's net worth?

The estimated net worth of Rowan E. Chapman is at least $463,845.24 as of August 17th, 2021. Ms. Chapman owns 10,356 shares of Natera stock worth more than $463,845 as of February 5th. This net worth estimate does not reflect any other investments that Ms. Chapman may own. Learn More about Rowan E. Chapman's net worth.

How do I contact Rowan E. Chapman?

The corporate mailing address for Ms. Chapman and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Rowan E. Chapman's contact information.

Has Rowan E. Chapman been buying or selling shares of Natera?

Rowan E. Chapman has not been actively trading shares of Natera over the course of the past ninety days. Most recently, Rowan E. Chapman sold 5,500 shares of the business's stock in a transaction on Friday, September 17th. The shares were sold at an average price of $120.77, for a transaction totalling $664,235.00. Learn More on Rowan E. Chapman's trading history.

Who are Natera's active insiders?

Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.

Are insiders buying or selling shares of Natera?

During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 62 times. They sold a total of 164,110 shares worth more than $6,807,068.72. The most recent insider tranaction occured on February, 1st when CFO Michael Burkes Brophy sold 19,326 shares worth more than $844,159.68. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.

Information on this page was last updated on 2/1/2023.

Rowan E. Chapman Insider Trading History at Natera

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2021Sell5,500$120.77$664,235.00View SEC Filing Icon  
8/17/2021Sell5,500$100.09$550,495.0010,356View SEC Filing Icon  
7/19/2021Sell3,000$108.32$324,960.00View SEC Filing Icon  
11/12/2020Sell3,000$83.48$250,440.003,000View SEC Filing Icon  
See Full Table

Rowan E. Chapman Buying and Selling Activity at Natera

This chart shows Rowan E Chapman's buying and selling at Natera by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Natera Company Overview

Natera logo
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $44.79
Low: $44.49
High: $46.21

50 Day Range

MA: $40.71
Low: $36.57
High: $46.55

2 Week Range

Now: $44.79
Low: $26.10
High: $74.82

Volume

663,436 shs

Average Volume

1,386,551 shs

Market Capitalization

$4.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26